Genitourinary Cancers

Treatment with atezolizumab did not improve clinical outcomes vs placebo following resection in patients with renal cell carcinoma at increased risk of recurrence.

Perioperative nivolumab did not improve recurrence-free survival compared with surgery alone in patients with renal cell carcinoma.

Moshe Ornstein, MD, MA, discusses toxicity concerns when treating renal cell carcinoma.

Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, discusses the evolving adjuvant treatment setting for renal cell carcinoma.

Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing rates, and the importance of proper multidisciplinary management during testing and when seeking to mitigate adverse effects.

Toni Choueiri, MD, discusses the future examination of adjuvant pembrolizumab in renal cell carcinoma.

Amir Goldkorn, MD, discusses the methods utilized to predict chemotherapy benefit in bladder cancer.

Successful, established immunotherapies that have been approved for use in the metastatic setting are rapidly moving forward into the adjuvant and neoadjuvant settings, and novel agents are emerging in later lines.

Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.

Eric Jonasch, MD, discusses the efficacy and safety of belzutifan observed in the LITESPARK-001 trial for patients with advanced clear cell RCC and the next steps for investigating belzutifan in this patient population.

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.

The Kidney Cancer Treatment guidelines, housed within the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, have been revised, granting tivozanib Category 1 status as a subsequent therapy for patients with renal cell carcinoma who have received at least 2 prior lines of treatment.

The combination of nivolumab and ipilimumab failed to elicit a statistically significant improvement in disease-free survival compared with placebo as adjuvant treatment in patients with localized renal cell carcinoma who had undergone a full or partial removal of the kidney and were at moderate or high risk of relapse, failing to meet the primary end point of part A of the phase 3 CheckMate-914 trial.

Toni Choueiri, MD, discusses the use of adjuvant pembrolizumab in renal cell carcinoma.

Toni K. Choueiri, MD, explains significant findings from the long-term efficacy analysis of the KEYNOTE-564 study and highlights the significance of these data for the field of RCC.

Brian I. Rini, MD, and Matthew Tucker, MD, sit down to discuss developing a career path and building a résumé, the value of writing review articles early in fellowship, the power of saying no, and the importance of saying yes.

Benjamin Garmezy, MD, discussed the positive trajectory of antibody-drug conjugates and immunotherapy in urothelial carcinoma, highlighting the importance of considering individual patient eligibility for treatments like first-line chemotherapy.

The FDA has granted a fast track designation to abelacimab for the treatment of thrombosis associated with cancer.

The addition of cabozantinib to nivolumab and ipilimumab generated a significant improvement in progression-free survival vs nivolumab/ipilimumab alone as a first-line treatment for patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma, meeting the primary end point of the phase 3 COSMIC-313 trial.

Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.

Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.

Among men in the United States, incidence-based mortality is growing for penile cancer even though incidence remained consistent from 2000 to 2018.

Batiraxcept will continue to be investigated in combination with cabozantinib, plus in combination with cabozantinib and nivolumab and as a single agent, in patients with advanced or metastatic clear cell renal cell carcinoma in a phase 2 study.